Effects of Covid-19 Prevention and Control Measures in Different Periods on the Diagnosis and Prognosis of NSTEMI Inpatients Complicated with Pulmonary Infection
WANG Qiang, YANG Cheng-jian, ZHANG Xiao-pu, et al
Department of Cardiology, The Third Affiliated Hospital of Soochow University, Changzhou 213003, Jiangsu
Abstract 【Objective】To analyze the diagnosis and prognosis of pulmonary infection in patients with non ST segment elevation myocardial infarction (NSTEMI) at different stages of New Coronavirus pneumonia (COVID-19). 【Methods】A retrospective analysis of 126 NSTEMI patients admitted to the Third Affiliated Hospital of Suzhou University under different prevention and control measures of COVID-19 was made into non COVID-19 epidemic group. (January 25, 2019 to February 25, 2019, non epidemic group, n=47), COVID-19 first responder group (January 25, 2020 to February 25, 2020, first responder group, n=42) and COVID-19 normal control group. (from January 25, 2021 to February 25, 2021, normal control group, n=37). The clinical characteristics, pulmonary infection and hospital mortality of the three groups were compared, and the influencing factors of NSTEMI inpatients complicated with pulmonary infection under epidemic prevention and control measures were analyzed. 【Results】 There were significant differences in visit time, bed time, heart rate and heart failure among the three groups (P<0.05). There was significant difference in the incidence of pulmonary infection among non epidemic group, primary response group and normal prevention and control group (P<0.001). Multivariate binary logistic regression analysis showed that visit time, heart failure and bed time were the influencing factors of pulmonary infection in NSTEMI patients (mean P<0.05). 【Conclusion】 The treatment measures during the first-class response of covid-19 prevention and control improved the detection rate of pulmonary infection in patients with NSTEMI, and did not increase the adverse prognosis in hospital in patients with NSTEMI complicated with pulmonary infection.
[1] MCMANUS D D. Recent trends in the incidence, treatment, and outcomes of patients with STEMI and NSTEMI[J].Am J Med,2011, 124(1):40-47.
[2] KRAHN C L, RAFFIN R P, SANTOS G S, et al. Isoflurane-loaded nanoemulsion prepared by high-pressure homogenization: investigation of stability and dose reduction in general anesthesia [J].J Biomed Nanotechnol,2012, 8(5):849-858.
[3] XIONG T Y, REDWOOD S, PRENDERGAST B, et al. Coronaviruses and the cardiovascular system: acute and long-term implications [J].Eur Heart J,2020, 41(19):1798-1800.
[4] 中华医学会心血管病学分会. 新型冠状病毒肺炎疫情防控期间心血管急危重症患者临床处理原则的专家共识[J].中华心血管病杂志,2020,48(3):189-194.
[5] ROFFI M, PATRONO C, COLLET J P, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC) [J].Eur Heart J,2016, 37(3):267-315.
[6] 蔡柏蔷, 李龙芸. 《协和呼吸病学》[M]. 第2版. 北京:中国协和医科大学出版社, 2011:231-240.
[7] 汪蛟龙,李枫,宁伟.急性心肌梗死患者血脂水平变化与PCI术后并发症及预后的相关性分析[J].医学临床研究,2019,36(4):710-712.
[8] MUSHER D M, ABERS M S, CORRALES-MEDINA V F. Acute Infection and Myocardial Infarction [J].N Engl J Med,2019, 380(2):171-176.
[9] CANGEMI R, CASCIARO M, ROSSI E, et al. Platelet activation is associated with myocardial infarction in patients with pneumonia [J].J Am Coll Cardiol,2014, 64(18):1917-1925.
[10] REN S, NEWBY D, LI S C, et al. Effect of the adult pneumococcal polysaccharide vaccine on cardiovascular disease: a systematic review and meta-analysis [J].Open Heart,2015, 2(1):e000247.
[11] BOOKER S, MURFF S, KITKO L, et al. Mouth care to reduce ventilator-associated pneumonia [J].Am J Nurs,2013, 113(10):24-30.
2021, Vol. 38 
